Nintedanib Zentiva (Nintedanib Esylate)

Nintedanib acts on pathways involved in fibrotic lung disease and tumor angiogenesis.

• Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in forced vital capacity.
• Non‑small cell lung cancer: used in combination regimens to inhibit tumor growth and angiogenesis.
• Progressive fibrosing interstitial lung disease: diminishes the rate of lung function loss in patients with a progressive fibrotic phenotype.

• Nintedanib inhibits multiple receptor tyrosine kinases—including vascular endothelial growth factor receptors (VEGFR 1‑3), fibroblast growth factor receptors (FGFR 1‑3), and platelet‑derived growth factor receptors (PDGFR‑α/β). By blocking these pathways, it reduces fibroblast proliferation, angiogenesis, and extracellular matrix deposition, thereby attenuating fibrotic remodeling and tumor vascularization.

Nintedanib may cause a range of adverse reactions.

Common Side Effects

• Diarrhea: frequent, watery stools that may require supportive care.
• Nausea: sensation of unease often accompanied by an urge to vomit.
• Decreased appetite: reduced desire to eat, potentially leading to weight loss.
• Elevated liver enzymes: increases in ALT/AST observed in routine monitoring.

Serious or Rare Side Effects

• Hepatic failure: severe liver injury requiring immediate medical attention.
• Major bleeding: gastrointestinal or intracranial hemorrhage, especially when combined with anticoagulants.
• Arterial thromboembolism: clot formation in arteries that can cause stroke or myocardial infarction.

Before initiating therapy, clinicians should consider several safety measures.

• Liver function monitoring: assess baseline enzymes and repeat periodically.
• Cardiovascular assessment: evaluate for hypertension or history of thrombotic events.
• Bleeding risk evaluation: avoid concomitant use with strong anticoagulants unless necessary.
• Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited.
• Storage: Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nintedanib can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nintedanib exposure.
• Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened risk of serious bleeding.
• Antiplatelet agents (e.g., clopidogrel, high‑dose aspirin): additive bleeding potential.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic levels.
• Calcium channel blockers (e.g., amlodipine): may modestly increase plasma concentrations.
• Statins (e.g., simvastatin, atorvastatin): monitor for liver enzyme changes.